



Jazz Pharmaceuticals Announces Presentation At The Jefferies 2012 Global Healthcare Conference In New York On June 7

June 05, 2012

DUBLIN, June 5, 2012 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) announced today that the company will make a presentation at the Jefferies 2012 Global Healthcare Conference in New York on Thursday, June 7, 2012 at 8:00 a.m. EST/ 1:00 p.m. GMT. Bruce Cozadd, Chairman and Chief Executive Officer, will provide a business update.

A live webcast of the presentation may be accessed from the Investors section of the Jazz Pharmaceuticals website at www.jazzpharmaceuticals.com. Please connect to the website prior to the start of the conference call to ensure adequate time for any software downloads that may be necessary to listen to the webcast.

An archived version of webcast will be available for at least one week on the Investors section of the company's website at www.jazzpharmaceuticals.com.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) is a specialty biopharmaceutical company focused on improving patients' lives by identifying, developing and commercializing products that address unmet medical needs. The company has a diverse portfolio of products in the areas of narcolepsy, chronic pain, psychiatry and women's health. The company's marketed products include: Xyrem® (sodium oxybate), Prialt® (ziconotide intrathecal infusion), FazaClo® (clozapine USP) HD and LD, Luvox CR® (fluvoxamine maleate) and Elestrin® (estradiol gel 0.06%).

SOURCE Jazz Pharmaceuticals plc

Ami Knoefler, Executive Director, Investor Relations & Corporate Communications, Jazz Pharmaceuticals plc, Ireland, + 353 1 638 1032, U.S., + 1 650 496 2947